Novel Agent Reduces Seizures in Treatment-Resistant Epilepsy
04/05/2026
Introducción Investigational azetukalner met its primary endpoint of reducing focal onset seizure frequency across two doses, initial findings from the
El instituto de investigación científica que podría recibir $4.2 mil millones en fondos públicos si los votantes de California aprueban…
Read more →Introducción Investigational azetukalner met its primary endpoint of reducing focal onset seizure frequency across two doses, initial findings from the
Introducción Cardiovascular protection with GLP-1 receptor agonists may benefit patients undergoing certain transcatheter procedures, according to two observational studies. When
Diabetic Patient Incident A CMS inspection report described how a diabetic patient with dementia at Eastland Healthcare and Rehabilitation Center